Scope and Development of Zollinger-Ellison Syndrome Market by Delveinsight | Companies – AstraZeneca, Takeda Pharmaceuticals

Zollinger-Ellison Syndrome Market

DelveInsight launched a new report “Zollinger-Ellison Syndrome Market Insights, Epidemiology, and Market Forecast-2032“.

Some of the key facts of the Zollinger-Ellison Syndrome Market Report:

• The annual incidence of gastrinomas is 0.5 to 2 per million population. 
• Majority of patients are diagnosed between the ages of 20 and 50, with a higher incidence in males as compared with females. 
• Approximately 80 percent of gastrinomas are sporadic, but 20 to 30 percent occur in association with multiple endocrine neoplasia type 1 (MEN1) 
• Although gastrinomas are one of the most common functional pancreatic neuroendocrine tumors, only 20 to 25 percent of gastrinomas arise in the pancreas. Approximately 50 to 88 percent of patients with sporadic ZES, and 70 to 100 percent of patients with ZES associated with MEN1, have duodenal gastrinomas. 
• In 5 to 15 percent of patients, gastrinomas arise in non-pancreatic, non-duodenal abdominal (stomach, peripancreatic lymph nodes, liver, bile duct, ovary), and extra-abdominal (heart, small cell lung cancer) locations.

Request for Sample Report: 

Key benefits of the Zollinger- Ellison Syndrome Market report:

• The study provides a detailed review of Zollinger- Ellison Syndrome, including its causes, signs and symptoms, pathophysiology, diagnosis, and current treatments.
• Study of the 7MM has offered comprehensive insight into the epidemiology and management of Zollinger- Ellison Syndrome.
• Furthermore, an all-inclusive description of both present and emerging Zollinger- Ellison Syndrome treatments is offered, as well as an analysis of future therapies that will have an influence on the current treatment landscape.
• The research includes a full evaluation of the Zollinger- Ellison Syndrome market, both historical and anticipated, as well as drug outreach in the 7MM population.
• By understanding the trends defining and driving the worldwide Zollinger- Ellison Syndrome market, the study gives you an advantage when formulating business plans.

Zollinger- Ellison Syndrome Overview

Zollinger-Ellison syndrome is a rare condition characterized by the formation of one or more tumors in the duodenum and pancreas. These tumors, known as gastrinoma, secrete a huge quantity of gastrin hormone, causing the stomach to produce an excessive amount of acid. Excess acid secretion causes peptic ulcers and diarrhea. Although Zollinger-Ellison syndrome can develop at any age, it is most commonly diagnosed between the ages of 20 and 50. Abdominal discomfort, diarrhea, acid reflux and heartburn, and digestive tract bleeding are all signs and symptoms of the condition. The cause and nature of Zollinger-Ellison syndrome are unknown. It can, however, be caused by an autosomal dominant hereditary condition known as multiple endocrine neoplasia type 1. (MEN-1). MEN-1 is present in around 25% of persons with Zollinger-Ellison syndrome.

The medical history, blood tests, upper gastrointestinal endoscopy, endoscopic ultrasound, and imaging tests such as magnetic resonance imaging (MRI), CT scan, and ultrasound are used to diagnose Zollinger-Ellison syndrome. The goal of Zollinger-Ellison syndrome treatment is to eliminate excess acid production, ulcer illness, and malignant tumors. Tumors are removed surgically, and excess acid output is reduced with medications such as proton pump inhibitors, H2-receptor antagonists, antacids, and chemotherapy. In patients with Zollinger-Ellison syndrome, the proton pump inhibitor class of drugs, which includes omeprazole, reduces acid production and facilitates ulcer healing.

Zollinger- Ellison Syndrome Market

The Zollinger- Ellison Syndrome market outlook section assists in developing a detailed understanding of historic, current, and forecasted Zollinger- Ellison Syndrome market trends by analyzing the impact of current Zollinger- Ellison Syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This section examines the Zollinger- Ellison Syndrome market trend of each marketed drug and late stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing market need, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, market impact, and key opinion leaders’ perspectives. Zollinger- Ellison Syndrome market statistics are supplied with pertinent tables and graphs to provide a comprehensive picture of the market at a glance. According to DelveInsight, the Zollinger- Ellison Syndrome market in 7MM is expected to undergo significant change between 2019 and 2032.

Learn more by requesting for sample @ Zollinger- Ellison Syndrome Market Landscape

Zollinger- Ellison Syndrome Companies 

• AstraZeneca 
• Takeda Pharmaceuticals

Zollinger- Ellison Syndrome Pipeline 

• Esomeprazole magnesium
• Lansoprazole

Know more about the pipeline therapies and recent developments @ Zollinger- Ellison Syndrome Pipeline Report

Table of Contents

1. Key Insights

2. Executive Summary of Zollinger-Ellison Syndrome

3. Competitive Intelligence Analysis for Zollinger-Ellison Syndrome

4. Zollinger-Ellison Syndrome: Market Overview at a Glance

5. Zollinger-Ellison Syndrome: Disease Background and Overview

6. Patient Journey

7. Zollinger-Ellison Syndrome Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Zollinger-Ellison Syndrome Unmet Needs

10. Key Endpoints of Zollinger-Ellison Syndrome Treatment

11. Zollinger-Ellison Syndrome Marketed Products

12. Zollinger-Ellison Syndrome Emerging Therapies

13. Zollinger-Ellison Syndrome: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Zollinger-Ellison Syndrome

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Media Contact

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/